Kilitch Drugs (India) (KILITCH) — concall transcript

📢 Key Event
Kilitch Drugs reported consolidated FY24 revenue of ₹154.37 crores, up from ₹117.78 crores in FY23, with PAT rising to ₹13.58 crores from ₹15.72 crores in the prior year.

🔄 What Changed

Revenue grew to ₹154.37 crores (FY24) from ₹117.78 crores (FY23), PAT increased to ₹13.58 crores from ₹15.72 crores, and export revenue contribution is projected to reach 60%-65% by FY25.

🔮 What's Next
Export revenue contribution to reach 60%-65% of total revenue by FY25; EBITDA margins projected to improve to 18%-22%; Ethiopian operations targeting 20%-25% margins; Khopoli plant validation starting May 25, 2024, with capacity to support 20-25% FY25 growth; land monetization valuation to be provided later.

💡 Investor Takeaway
Shareholders should note that export growth and new capacity expansions are central to Kilitch’s strategy, with Ethiopia and Khopoli driving future revenue and margin expansion.

Kilitch Drugs reported consolidated FY24 revenue of ₹154.37 crores, up from ₹117.78 crores in FY23, with PAT rising to ₹13.58 crores from ₹15.72 crores in the prior year. Management highlighted a 60%-65% export revenue contribution by FY25, driven by a $9.1 million Ethiopian government tender executed in Q2 FY24, and projected 18%-22% EBITDA margins as Ethiopian operations target 20%-25% margins. The Khopoli plant’s first floor slab is complete, with validation starting May 25, 2024, targeting 260 million tablets, 31 million vials, and 47 million ampoules annually to support 20-25% FY25 growth. Land monetization near Addis Ababa is under review, with current market value potentially exceeding historical INR50 crores.

📄 View Original Announcement (PDF)

📊 Stock Analysis — KILITCH ✨ Ask AI About This

About Kilitch Drugs (India) Ltd (KILITCH)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹599.24 Cr P/E: 13.7 ROE: 10.4% ROCE: 11.9%

View full KILITCH stock details →

📡 Get AI alerts when KILITCH files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track KILITCH — Free

💡 Ask AI about this filing

"How will the $9.1M Ethiopian tender impact quarterly cash flow?" "What is the timeline for full Khopoli plant capacity utilization?" "When will land monetization valuation be disclosed?"

Ask AI Free →

📊 More KILITCH filings

See all KILITCH filings →

🔥 Also filed on 31 March 2024

M&M Mahindra & Mahindra Ltd concall transcript SBIN State Bank of India concall transcript ULTRACEMCO UltraTech Cement Ltd concall transcript TITAN Titan Company Ltd concall transcript ETERNAL Eternal Ltd concall transcript BEL Bharat Electronics Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when KILITCH files new disclosures

Track KILITCH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track KILITCH — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd